Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Patients With Radicular Chronic Low Back Pain

The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) with a radicular component for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Start Date01 Sep 2026

Sponsor / Collaborator

Vertanical GmbH

NCT05432284

/ Not yet recruitingPhase 1IIT

Behavioral Pharmacology of THC and Beta-Myrcene

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

Start Date01 Jul 2026

Sponsor / Collaborator

The Johns Hopkins University

[+1]

NCT03734731

/ Not yet recruitingNot Applicable

Clinical Trial Policy Study for the Objective Comparison of Cannabis Vs Opioids (CVO) Pain Management and Therapy Types for Circulatory and Chronic Pain Issues

Our purpose for the study is to find safer, less intrusive, better preforming non-addictive products, as an alternative therapy for pain relief and to help alleviate the opioid epidemic ongoing in America today.

Start Date03 Jun 2026

Sponsor / Collaborator

American Association of Sensory Electrodiagnostic Medicine

100 Clinical Results associated with Dronabinol

100 Translational Medicine associated with Dronabinol

100 Patents (Medical) associated with Dronabinol

12,399

Literatures (Medical) associated with Dronabinol

01 Jul 2026·TALANTA

Portable voltammetric method for the simultaneous determination of Δ9-Tetrahydrocannabinol and cannabidiol in alkaline medium using unmodified screen-printed carbon electrodes

Article

Author: Lucca, Bruno G ; Pedão, Evandro R ; Lima, Camila D ; Brandão, Mariane O ; Gebara, Sâmya S ; Guerbas, Fernanda M R ; Moraes, Natália C ; Arantes, Luciano C ; Dos Santos, Wallans T P

Simultaneous detection of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is crucial for the analysis of seized materials and cannabis-based preparations. To address this need, a simple, rapid, and selective electrochemical method was developed for the preliminary detection and quantification of both cannabinoids. The proposed method employs unmodified carbon screen-printed electrodes (carbon-SPEs) in a strongly alkaline medium (0.5 mol L^-1 NaOH solution). The electrochemical behaviors of THC and CBD were investigated over a wide range of pH values, enabling a simultaneous detection with distinct peak potentials observed on carbon-SPE (vs Ag). THC exhibited a single irreversible oxidation process (O_1T) on the carbon-SPE surface, whereas CBD showed, for the first time, five well-defined electrochemical processes, with two reduction processes (R_1C and R_2C) and three oxidation processes (O_1C, O_2C and O_3C). Square wave voltammetric technique was optimized for the simultaneous determination of THC and CBD using their oxidation processes at O_1T and O_3C on carbon-SPE, with limits of detection of 0.09 μmol L^-1 and 2.72 μmol L^-1, respectively. Moreover, consistent electrochemical responses were obtained using either the same (N = 5) or different SPEs (N = 3), with RSDs lower than 5.6% and 2.0 % for peak currents and peak potentials, respectively. Method applicability was confirmed by analyzing thirty-five (35) real seized samples and seven cannabis-based products, showing good agreement with GC-MS results. Addition-recovery studies using real seized samples yielded values close to 100 % for both analytes: 102 ± 2 % for O_1T (THC) and 103.3 ± 0.8 % for O_3C (CBD). These findings highlight the method's potential as a reliable, low-cost, and field-deployable tool for forensic screening and quality control in cannabis-derived products.

01 Jun 2026·International Journal of Pharmaceutics-X

Liquisolids as a platform for the formulation of cannabis tablets

Article

Author: Steffens, Kristina E ; Appelhaus, Jan ; Wagner, Karl G

Mesoporous silica-based liquisolids offer an effective method for transforming liquid or sticky actives, such as cannabis extracts, into free-flowing powders. This approach broadens the formulation strategies available for these actives, which are typically limited to liquid formulations or soft gelatin encapsulation, by facilitating the formulation of tablets. However, tableting liquisolids is challenging due to issues including low tensile strength, capping and delamination. Overcoming these challenges requires careful selection of excipients and tableting parameters to produce tablets with sufficient tensile strength while also maintaining high Overall Liquid Load. In our study, we utilized a 65/35 volumetric ratio of 0.75 mL/g liquid loaded Syloid® XDP 3050 silica and Vivapur® 101 as a binder/filler to formulate cannabis liquisolid tablets with a target THC dose of 10 mg per tablet. Findings indicated that a 4% concentration of Kollidon® CL-F was optimal for disintegration, while 0.5% magnesium stearate proved to be the most effective lubricant concentration. Utilizing a rotary press compaction cycle on a StylOne® compaction simulator, we found precompression around half the main compaction pressure allowed for maximizing tableting speed while maintaining high tensile strength and keeping tablet defects to a minimum. The resulting cannabis liquisolid tablets demonstrated a tensile strength of 1.58 N/mm² and a high Overall Liquid Load of 38.4% (V/V). They exhibited acceptable disintegration time, friability, dissolution behavior and were proven to remain stable for 30 days at 40 °C and 0% humidity. Under refrigerated conditions, stability is predicted to be >3 years.

01 Jun 2026·Toxicology reports

The toxicology of orally administered Δ9-tetrahydrocannabinol in sheep

Article

Author: May, Christopher D ; Krebs, Gaye L ; Blake, Bronwyn L ; Noble, Glenys K ; Stevens, Sarah A ; Petzel, Christopher E ; Tai, Zi Xuan ; Edwards, Scott H ; Scrivener, Colin J ; Dods, Kenneth C ; Warne, Leon N

Introduction:

As part of a larger study to assess the potential value of industrial hemp biomass (the low Δ⁹-tetrahydrocannabinol (Δ⁹-THC) variety of Cannabis sativa L.) as a feed for ruminants, a pharmacokinetics study of Δ⁹-THC, one of the main cannabinoids of interest, was undertaken. In undertaking this study, the toxicology of orally administered Δ⁹-THC was incidentally investigated and was discussed in the current paper.

Methods:

Eight Merino ewes were administered with two per os (PO) doses of 88.5 mg Δ⁹-THC/kg bodyweight (BW) 12 h apart. Blood samples were taken periodically to determine the pharmacokinetics of Δ⁹-THC but also to check blood troponin I concentrations post dose administration as in the pharmacokinetics study there were adverse effects to the heart following intravenous administration of Δ⁹-THC.

Results:

Following the PO dose of Δ⁹-THC, the pharmacokinetics were able to be determined (and were published separately); however, significant adverse clinical signs were observed in the sheep. Clinical signs included ataxia (stumbling, swaying), abnormal posture (head held low, head resting on the wall of the pen, back legs crossed over), somnolence, wool pulling, increased salivation, a prolonged reduction in feed intake and consequent decrease in BW. Plasma troponin I concentrations were elevated in three of the eight sheep following the PO dose of Δ⁹-THC.

Conclusions:

The adverse clinical signs noted have implications for iHemp biomass as a potential feed for ruminants due to both animal health and production effects. Further research is required to investigate appropriate feeding strategies for iHemp biomass to be utilised as a feed for ruminants.

591

News (Medical) associated with Dronabinol

11 Mar 2026

·www.sciencedaily.com

Cannabis study finds THC can create false memories

THC doesn’t just blur memories—it can create new ones that never happened. In a controlled experiment, cannabis users were much more likely to recall words that were never shown and struggled with tasks like remembering to do something later. Researchers found that THC disrupted many different memory systems at once. Surprisingly, moderate doses caused memory problems similar to higher doses.Smoking cannabis may do more than make memories fuzzy. It may actually alter how memories form and are recalled. A new study from Washington State University found that people who consumed THC were more likely to recall words that were never shown to them and had more trouble completing everyday memory tasks, such as remembering to do something later. Published in the Journal of Psychopharmacology, the research provides one of the most detailed examinations to date of how cannabis influences memory. The results indicate that cannabis affects not only simple recall, like remembering a list of words, but also several forms of memory that people rely on throughout the day. These include remembering appointments, keeping track of conversations, and identifying where information originally came from. Researchers were also surprised to see no meaningful differences between participants who consumed 20 milligrams of THC and those who consumed 40 milligrams. This finding suggests that even moderate amounts of THC may significantly interfere with memory. Study Examines Multiple Memory Systems "Most previous studies have only looked at one or two types of memory, like recalling lists of words," said Carrie Cuttler, senior author of the study and an associate professor of psychology at WSU. "This is the first study to comprehensively examine many different memory systems at once, and what we found is that acute cannabis intoxication appears to broadly disrupt most of them." To investigate these effects, Cuttler and co-author Ryan McLaughlin, an associate professor in the Department of Integrative Physiology and Neuroscience at WSU, recruited 120 regular cannabis users. Participants were randomly assigned to vaporize placebo cannabis, 20 milligrams of THC, or 40 milligrams of THC in a double-blind experiment. After consuming the assigned substance, participants completed roughly an hour of memory tests. The assessments measured several types of memory, including verbal, visuospatial, prospective, source, false, episodic content, and temporal order memory. People who consumed cannabis performed significantly worse than those who received the placebo on most of the tests. In total, cannabis affected the majority of the memory measures, with significant differences appearing in 15 of the 21 tests. Cannabis Linked to False Memories and Source Confusion The most pronounced effects were seen in false memory and source memory, which help people accurately recall information and determine where that information came from. In one test, participants listened to lists of related words that were connected by a theme, but the central keyword tying them together was never spoken. Later, individuals who had consumed cannabis were more likely to say they remembered hearing words that had not been presented. "I found it was really common for people to come up with words that were never on the list," Cuttler said. "Sometimes they were related to the theme of the list, and sometimes they were completely unrelated." Participants who used cannabis also had more difficulty identifying where previously learned information originated. Problems with source memory can make it harder to determine whether information came from a trusted source, a conversation, or something encountered online. These kinds of memory distortions could have serious implications in situations where accurate recall is essential. For example, errors in memory or suggestive questioning during eyewitness interviews can influence how events are remembered. Impacts on Everyday Memory Tasks The researchers also observed impairments in prospective memory, which is the ability to remember to perform tasks in the future. This type of memory is involved in everyday responsibilities such as taking medication, attending meetings, or stopping at the store on the way home. "These are things we rely on constantly in our day-to-day lives," Cuttler said. "If you have something you need to remember to do later, you probably don't want to be high at the time you need to remember to do it." One form of memory called episodic content memory, which involves recalling personal experiences, did not show a significant effect in this study. Cuttler noted that additional research is needed before drawing firm conclusions about that type of memory. Cannabis Use Is Growing but Research Gaps Remain The study comes at a time when cannabis use is becoming increasingly common in states such as Washington. Even though legalization has expanded across North America, many short term cognitive effects of cannabis remain unclear. One reason for the limited research is that cannabis is still classified as a Schedule I substance under federal law, which has historically restricted scientific study. "We're living in a state where cannabis use is very common, but there's still a lot we don't know about its acute effects," Cuttler said. "The goal is to help people make informed decisions about the risks and benefits."

10 Mar 2026

·www.globenewswire.com

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. (“CliniQ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing of the transaction (the “Transaction”). CliniQ is a quantum technology company holding patents from Ramot at the Tel Aviv University, in the field of quantum simulation and quantum Monte Claro. CliniQ develops a next-generation platform to transform clinical trials with the power of quantum computing. Its aim is to unlock insights hidden in massive, complex datasets to design smarter, faster, and more adaptive studies. Transaction Overview Under the SPA, NeuroThera will acquire 56,375 CliniQ Shares (the "Purchased Shares"), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQ from certain shareholders of CliniQ (collectively, the "Selling Shareholders"). In consideration for the Purchased Shares, NeuroThera will issue an aggregate of 56,600,000 common shares from the capital of NeuroThera (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9,459,954.20 based on the volume weighted average trading price of the NeuroThera's common shares on the TSX Venture Exchange (the "TSXV") for the 20 trading days immediately preceding the date of the determination. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2,500,000 in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of NeuroThera at the sole discretion of NeuroThera, contingent upon the achievement of the certain milestones, including $500,000 for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1,500,000 in the aggregate filed during the Earn-Out Period (as defined below); and an amount equal to 7.0% of any fundraising proceeds raised by NeuroThera, up to a maximum of $1,000,000 in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction (the “Earn-Out Period”). Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to satisfaction or waiver of all closing conditions. The closing of the Transaction is anticipated to be on or about March 31, 2026, unless otherwise agreed by the parties in writing. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. About NeuroThera Labs Inc. NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the closing of the Transaction, which is subject to satisfaction or waiver of all closing conditions, and timing thereof and that the Selling Shareholders may be entitled to the Earn-Out Payments. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

02 Mar 2026

·www.globenewswire.com

SciSparc Announces 1-for-9 Reverse Share Split

Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it intends to effect a one-for-nine (1-for-9) reverse share split (the “Reverse Share Split”) of the Company’s issued and outstanding ordinary shares, no par value per share (the “Ordinary Shares”), effective at the market open on March 4, 2026. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing trading symbol “SPRC” and will begin trading on a split-adjusted basis at the market open on March 4, 2026. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M82618139. The Reverse Share Split was approved by the Company’s shareholders at the Company’s Annual General Meeting of Shareholders held on June 26, 2025, to be effected at the board of directors’ discretion within the approved parameters. The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company’s amended and restated articles of association, as currently in effect (the “Articles”), which, as of the date hereof, consists of 2,000,000,000 Ordinary Shares. The Reverse Share Split will affect all shareholders uniformly and will not alter any shareholder’s percentage of ownership interest in the Company’s Ordinary Shares, except for minor changes due to the treatment of fractional shares as described below. The number of issued and outstanding Ordinary Shares will be reduced from 5,089,501 Ordinary Shares to approximately 565,500 Ordinary Shares following the Reverse Share Split (subject to any further adjustments due to the treatment of fractional shares). In accordance with the Articles, no fractional Ordinary Shares will be issued as a result of the Reverse Share Split and all fractional Ordinary Shares shall be rounded to the nearest whole Ordinary Share, at the DTC participant level. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase Ordinary Shares. No fractional Ordinary Shares will be issued upon exercise of warrants or options. As to any fraction of an Ordinary Share which a holder would otherwise be entitled to purchase upon exercise, the Company will round up to the nearest whole Ordinary Share, according to the terms of the warrant or option. Shareholders holding their shares in book-entry form, through a brokerage account, or in “street name” are not required to take any action, as the exchange will be processed automatically by their respective brokers or custodians. For questions or additional information regarding the exchange process, shareholders are encouraged to contact the Company’s transfer agent, VStock Transfer, LLC with a mailing address of 18 Lafayette Place, Woodmere, New York 11598. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when discussing the anticipated effective date of the Reverse Share Split and the date that trading of the Ordinary Shares will begin on a split-adjusted basis. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

100 Deals associated with Dronabinol

External Link

KEGG	Wiki	ATC	Drug Bank
D00306	Dronabinol	A04AD10	DB00470

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anorexia	United States	Alkem Laboratories Ltd.	31 May 1985
Nausea	United States	Alkem Laboratories Ltd.	31 May 1985
Vomiting	United States	Alkem Laboratories Ltd.	31 May 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	NDA/BLA	Canada	Tetra Bio-Pharma, Inc.	01 May 2023
Agitation in Dementia	Phase 3	Australia	Benuvia Therapeutics, Inc.	01 May 2026
Alzheimer Disease	Phase 3	Australia	Benuvia Therapeutics, Inc.	01 May 2026
Sleep Apnea, Obstructive	Phase 3	United States	RespireRx Pharmaceuticals, Inc.	01 Feb 2023
Low Back Pain	Phase 3	Germany	Vertanical GmbH	07 Jul 2021
Decrease in appetite	Phase 3	Europe	Solvay SA	15 Feb 2007
Tourette Syndrome	Phase 2	United States	SciSparc Ltd.	01 Feb 2017
Depressive Disorder	Phase 2	United States	Unimed Pharmaceutical, Inc.	29 Jul 1996
Parkinson Disease	Preclinical	Canada	Pike Therapeutics, Inc.	01 Nov 2024
Cognition Disorders	Preclinical	Israel	Therapix Biosciences Ltd /Non-Pain Assets/	13 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Phase 2	Chronic Pain \| Anemia, Sickle Cell	30	Dronabinol	hrbypiwahr(vgoonxpope) = vvaaryjbbr ewwoqmpvgd (sizakrijgu ) View more	Positive	06 Dec 2025
				Placebo	hrbypiwahr(vgoonxpope) = weiqobvenn ewwoqmpvgd (sizakrijgu ) View more
NCT03978156 (Pubmed \| Pilot Feasibility Stud)	Phase 2	Anemia, Sickle Cell	6	Dronabinol	xritqggovp(zxzczljsis) = jdixxqnytp vxdqqxrgba (mtoitsftou ) View more	Positive	12 Nov 2025
NCT02792257 (THC-AD, Pubmed \| Am J Geriatr Psychiatry)	Phase 2	Agitation in Dementia	75	Dronabinol	lftighuocc(ppglkctgba): Difference = -1.26, P-Value = 0.094 View more	Positive	01 Nov 2025
				Placebo
NCT05610813 (Pubmed \| Pain Ther)	Phase 3	Low Back Pain	384	VER-01	blkfeobrme(iouutzuwer) = qomddjjiio utxnrroeek (dhmyolmnjn ) View more	Positive	30 Sep 2025
				Opioids	ljpeoyzqri(eosrtznydc) = mdewxwumdr ordamerwlt (esqoyainrg ) View more
NCT05477875 (CTgov)	Phase 2	Myopia \| Hyperopia \| Pain, Postoperative	35	Cannabidiol (Cannabidiol)	owxepftgdx(heotuvdbtj) = dwgjqqvasb zymyanjhdn (cvxquayojo, 0.95) View more	-	07 Aug 2025
				Tylenol T3 (Tylenol T3)	owxepftgdx(heotuvdbtj) = nkqvcdvtrz zymyanjhdn (cvxquayojo, 0.89) View more
NCT05820685 (DOPE, CTgov)	Phase 4	Pain	484	Standard of Care (Standard of Care)	qgtysmttnw(wrinlskjbs) = sfvzmwfjdv wylubuhcbc (djweoxpwuz, wowjbgwzzp - aefprdjust) View more	-	11 Jun 2025
				Standard of Care+Dronabinol (Standard of Care + Dronabinol)	qgtysmttnw(wrinlskjbs) = vihgkpikmu wylubuhcbc (djweoxpwuz, izpmyvazlg - nxonrjbejt) View more
NCT02792257 (THC-AD, CTgov)	Phase 2	Alzheimer Disease \| Agitation	84	Dronabinol (Dronabinol)	panlojoolo(aayddjewvi) = zscbhmcddx yggsunhqwl (pzrjegzpfn, 4.12) View more	-	09 May 2025
				Placebo (Placebo)	panlojoolo(aayddjewvi) = dlvwmbxlwy yggsunhqwl (pzrjegzpfn, 4.18) View more
NCT03705559 (CTgov)	Phase 1	Marijuana Abuse	10	Placebo (Placebo/Placebo)	ahyrygvuid(czsdztmkyi) = fwgmwmmvlo mwwyxvlxem (pkbkphxdfk, 1.83) View more	-	10 Apr 2025
				Placebo+THC (THC 10mg/Placebo Opioid)	ahyrygvuid(czsdztmkyi) = uakaudvihc mwwyxvlxem (pkbkphxdfk, 10.03) View more
NCT02817698 (CTgov)	Early Phase 1	Smoking \| Marijuana Abuse \| Unspecified drug dependence	25	cannabis	cfmjbsmmja(mghgikzluq) = uhnjmbuhxj ebatdgmwfx (ebaxohmskg, syhewldmun - bwxiynfvnd) View more	-	12 Dec 2024
NTIASD1 (Company_Website) Manual	Phase 1/2	Autism Spectrum Disorder	14	NTI164	jknlhzyacq(rtacqahust) = qxyomxvyxt yjrffmhqkg (zvpjttfznq )	Positive	01 Dec 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis